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Background: Accumulating evidence indicates that components of the systemic inflammatory response, such as
C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR), have been associated with prognosis of various
cancers. We aimed to elucidate whether CRP and NLR could serve as potential surrogate markers for response and
survival in patients with hepatocellular carcinoma (HCC).
Methods: The study population consisted of 318 consecutive patients with HCC. CRP and NLR were measured at
baseline with follow-up measurements.
Results: With the mean follow-up of 13.9 months, the median survival time was 13.8 months. Child-Pugh class,
tumor size > 5 cm, tumor multiplicity, presence of portal vein thrombosis, α-fetoprotein > 200 ng/mL, CRP > 6.3 mg/
L and NLR > 2.3 were identified as independent factors for worse survival of HCC (all p < 0.05). Patients with
elevated CRP (> 6.3 mg/L) and elevated NLR (> 2.3) had a significantly shorter overall survival than those with low
CRP and low NLR (all p < 0.001). The combined use of CRP and NLR provided incremental prognostic information.
With significant inter-correlations, levels of CRP and NLR escalated with aggravating Child-Pugh class from A to C or
progressing tumor stage from I to IV. CRP and NLR on baseline and serial measurements were well predictive of
treatment response (p < 0.001).
Conclusions: CRP and NLR are independent indicators for survival in HCC patients, reflecting tumor burden and
hepatic reserve. Their role in predicting tumor response and survival is more enhanced when used in combination.
This study suggests that CRP and NLR are important prognostic biomarkers for HCC.
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SurvivalBackground
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy and the third leading cause of cancer-related
deaths worldwide [1]. Although there have been many
advances in the treatment of HCC, the outcome is still not
satisfactory [1,2]. Since a long lasting inflammatory process
like cirrhosis continually induces hepatocarcinogenesis,* Correspondence: garden@catholic.ac.kr
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reproduction in any medium, provided the orthere are limitations on curative therapy. Besides known
prognostic factors representing tumor status and liver
function [3], it is now clear that inflammation plays a sig-
nificant role in tumor progression [4]. In this situation, C-
reactive protein (CRP) and neutrophil-to-lymphocyte ratio
(NLR), indicators of inflammation, have been suggested as
surrogate markers for a relationship between inflammation
and cancer [5].
CRP has been identified as a prognostic factor for HCC
[6-10] as well as other various malignancies, such as
gastrointestinal tumor, renal cell cancer and ovarian can-
cer [5,11]. It is an acute phase reactant, synthesized in the
liver [12], and regulated by proinflammatory cytokines,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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carcinogenesis [13]. The NLR has recently been evaluated
as a predictor of prognosis of HCC [14-16] as well as
other malignancies like colorectal cancer, gastric cancer,
breast cancer and ovarian cancer [5,17-20]. It has been
shown that high levels of NLR could predict a risk of recur-
rence and survival in patients with various malignancies.
HCC is unique among other cancers, in that its prog-
nosis not only depends on the tumor characteristics but
also on the hepatic functional reserve. In this respect, it
seems to be more relevant to understand inflammatory
process in hepatocarcinogenesis and evaluate its effect
on the patient prognosis. To date, there have been no
comprehensive data on the relationship between the in-
flammatory markers and hepatic reserve and tumor sta-
tus in HCC. In addition, the significance of both CRP
and NLR in HCC survival has not yet been explicitly
studied in one research.
In the present study, we therefore evaluated the clin-
ical value of CRP as well as NLR measured at the same
point in time in clinical outcome in a large number of
patients with HCC. In addition, changes in CRP and
NLR after treatment were examined in relation to the
treatment response. The present findings show the prog-
nostic utility of both CRP and NLR as a surrogate
marker for efficacy in treatment as well as HCC survival.
Methods
Patients
A database of all 318 patients with newly diagnosed
HCC between January 2007 and December 2010 at
Incheon St. Mary’s hospital, Incheon, South Korea was
prospectively collected and retrospectively analyzed. The
diagnosis of HCC was made based on histological evi-
dence or elevated serum α-fetoprotein (AFP) levels
(> 200 ng/mL) with typical radiological findings (arterial
enhancement with portal washout) [21]. The staging of
tumor was determined according to the TNM classifica-
tion of Malignant Tumors/International Union Against
Cancer (UICC) classification system, which is widely
used in Korea [21]. Our main treatment modality for
HCC was transarterial chemotherapy (TAC)-based loco-
regional therapy. The chemotherapeutic regimen used
for TAC was intra-arterial chemotherapy using doxo-
rubicin (50 mg) for patients who had multifocal tumors
≤ 10 cm or a combination of epirubicin (50 mg) and cis-
platin (60 mg) for patients with Child-Pugh class A who
had large tumors (> 10 cm) with or without portal vein
thrombosis (PVT). Patients with PVT or extrahepatic
metastasis were considered for radiotherapy in addition
to TAC. No patients treated with loco-regional therapy
were given glucocorticoids. Each patient provided
informed consent to participate in the study. This study
was approved by the Ethics Committees of The CatholicUniversity of Korea in accordance with the 1975 Declar-
ation of Helsinki.Methods
Laboratory data including CRP and NLR were obtained
from the study subjects prior to the initiation of treatment
and at each treatment cycle. All serum samples were
measured as fresh state. Serum CRP level was determined
as highly-sensitive CRP (hs-CRP) by immunoturbidimetric
assay using CRPH (C-Reactive Protein, High Sensitivity)
reagent (Beckman Coulter, Inc., Fullerton, CA USA; limit
of detection, 0.08 mg/L). The NLR was calculated by div-
iding the neutrophil count by the lymphocyte count. CRP
and NLR measurements were obtained without demon-
strable infection. To evaluate the relationship between
changes in CRP levels and NLR and tumor response, serial
measurements of the CRP levels and NLR were carried
out 3 to 4 months after treatment. Based on the modified
Response Evaluation Criteria In Solid Tumors (RECIST)
criteria [22], patients with complete response and partial
response after treatment were grouped together as
responders, whereas patients with stable disease and pro-
gressive disease were defined as non-responders.Statistical analysis
SPSS version 18 (SPSS Inc., Chicago, IL, USA) and
MedCalc version 11.6.1 (MedCalc Software Inc.,
Mariakerke, Belgium) were used to analyze the data. The
cut-off values of CRP and NLR were determined using
receiver operating characteristic (ROC) curve analysis.
The optimal cut-off levels for CRP and NLR were
established at 6.3 mg/L and 2.3, respectively, and these
cutoff values were used to categorize the high and low
CRP or NLR groups. Univariate analysis was performed
to assess significant differences in clinical characteristics.
A multivariate analysis was performed by Cox regression
for variables significant on univariate analysis. Overall
survival was calculated from the date of diagnosis to the
date of death or last follow-up. For patients undergoing
liver transplantation, follow-up was censored at the time
of transplantation. To compare overall survival rates
according to CRP or NLR, the data were analyzed by the
Kaplan-Meier method, and the differences in survival
between groups were compared by the log-rank test.
Correlations between the inflammatory markers and
Child-Pugh class and tumor stage were assessed using
Spearman correlation coefficients. Serial changes in CRP
levels and NLR were evaluated using repeated measures
ANOVA. Each continuous variable was appropriately
categorized in order to achieve the largest statistical
power. A p value of less than 0.05 was considered to be
statistically significant.
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Baseline characteristics
A total of 318 patients were consecutively enrolled in this
study. Table 1 shows baseline characteristics of the entire
study population. Patient age ranged from 32 to 89 years
(median: 58 years) and 240 (75.5%) of the patients were
males. At diagnosis, 200 (62.9%) patients were classified into
Child-Pugh class A; 91 (28.6%) patients into Child-Pugh
class B; 27 (8.5%) patients into Child-Pugh class C. The me-
dian tumor size was 5.5 (0.8–26.5) cm and the number of
patients with solitary tumor was 144 (45.3%). Each case of
presence of PVT and extrahepatic metastasis was 107
(33.6%) and 62 (19.5%), respectively. Distribution of tumor
stage after UICC (I/II/III/IVa/IVb) classification in our
patients was as follows: 41 (12.9%)/76 (23.8%)/85 (26.7%)/64
(20.1%)/52 (16.4%), respectively. The median levels of serum
AFP, CRP and NLR were 92.3 (1.6–2,753,500) ng/mL, 4.7
(0.1–343.6) mg/L and 2.6 (0.6–49.9), respectively. The
allocated treatments for the 318 patients were surgical resec-
tion (n = 41), liver transplantation (n = 10), TAC-based loco-
regional therapy (n = 221), and supportive care (n = 46).
Factors affecting prognosis of HCC in the whole study
population
To identify factors for HCC survival, 12 potential variables
of interest were analyzed, as listed in Table 2. Of these,
elevated ALT, Child-Pugh class, tumor size, tumor multi-
plicity, presence of PVT, presence of metastasis, elevated
AFP, high CRP and high NLR were significantly associated
with poorer survival. With multivariate analysis using a
Cox regression model, Child-Pugh class (p < 0.001; Hazard
ratio [HR] 1.711; 95% confidence interval [CI] 1.377–
2.125), tumor size > 5 cm (p = 0.003; HR 1.778; 95% CI
1.209–2.615), tumor multiplicity (p = 0.035; HR 1.391;
95% CI 1.023–1.892), presence of PVT (p = 0.001; HR
1.827; 95% CI 1.284–2.598), AFP > 200 ng/mL (p = 0.001;
HR 1.734; 95% CI 1.248–2.407), CRP > 6.3 mg/L
(p = 0.027; HR 1.519; 95% CI 1.049–2.199) and NLR > 2.3
(p = 0.009; HR 1.601; 95% CI 1.124–2.280) were identified
as independent poor prognostic factors for HCC (Table 2).
When we included the combination of high CRP and high
NLR as a variable into the analysis, the combination of
CRP and NLR (p < 0.001; HR 1.905; 95% CI 1.345–2.697)
together with Child-Pugh class (p < 0.001; HR 1.806; 95%
CI 1.464–2.228), tumor size > 5 cm (p = 0.002; HR 1.858;
95% CI 1.258–2.743), presence of PVT (p < 0.001; HR
1.893; 95% CI 1.329–2.697) and AFP > 200 ng/mL
(p < 0.001; HR 1.821; 95% CI 1.324–2.504) were identified
as independent factors for worse survival instead of CRP
or NLR alone.
Overall survival according to CRP and NLR level
During the mean follow-up period of 13.9 months, 202
(63.5%) of the patients died. The median survival timewas 13.8 months. Since CRP and NLR played a signifi-
cant role in predicting the HCC survival, we evaluated
the differences in survival according to the low versus
high CRP and NLR levels among the entire group. As
depicted in Figure 1A, the median survival of patients
with elevated CRP (> 6.3 mg/L) was 6.0 months, which
was significantly shorter than 26.9 months for patients
with a low level of CRP (log-rank test, p < 0.001). Like-
wise, the survival in the elevated NLR (> 2.3) group was
significantly worse than that in the low NLR group, with
the median survival times of 7.9 versus 32.5 months
(log-rank test, p < 0.001; Figure 1B). The statistical
differences for survival by the levels of CRP and NLR
were still maintained in the patients receiving treatments
as well as the entire patients (data not shown). An add-
itional analysis was done to examine the synergistic ef-
fect of a combined use of CRP and NLR on the patient
outcome. When the Kaplan-Meier survival curves were
plotted over time, there was a stepwise increase in the
overall survival rate from both high CRP (> 6.3 mg/L)
and NLR (> 2.3) levels, one of them and to both low
CRP (≤ 6.3 mg/L) and NLR (≤ 2.3) levels, indicating the
benefit of the combined use of the two inflammatory
markers (Figure 1C).Correlation of CRP and NLR with Child-Pugh class and
tumor stage
The relationship of CRP and NLR with Child-Pugh class
and tumor characteristics, which were the two major
determinants of the prognosis of patients with HCC,
were evaluated. There was a significant correlation be-
tween CRP concentrations and Child-Pugh class or
tumor stage (r = 0.311, p < 0.001; r = 0.475, p < 0.001, re-
spectively). As shown in Figures 2A and 2B, the level of
CRP tended to increase as liver disease progressed from
Child-Pugh class A to C as well as tumor stage from I to
IV. Likewise, there was also a significant correlation be-
tween NLR and Child-Pugh class or tumor stage
(r = 0.306, p < 0.001; r = 0.358, p < 0.001, respectively).
Figure 2C and Figure 2D illustrate the escalating values
of NLR with aggravating Child-Pugh class from A to C
or progressing tumor stage from I to IV. When analyzed
regarding the relationship between the CRP levels and
NLR, there was a significant positive inter-correlation
between CRP and NLR levels (r = 0.570, p < 0.001;
Figure 2E).Tumor response according to CRP and NLR level
When baseline levels of CRP and NLR were analyzed for
tumor response, there were more non-responders in the
group with serum CRP > 6.3 mg/L and NLR > 2.3,
whereas there were more good responders in the group
with both baseline serum CRP ≤ 6.3 mg/L and NLR ≤ 2.3
Table 1 Baseline patient characteristics according to total patients, CRP and NLR level
Characteristics Total patients (n = 318) Patients grouped by CRP level (n = 318) Patients grouped by NLR level (n = 318)
CRP ≤ 6.3 mg/L (n = 171) CRP > 6.3 mg/L (n = 147) NLR ≤ 2.3 (n = 129) NLR > 2.3 (n = 189)
Sex (male:female) 240:78 122:49 118:29 93:36 147:42
Age (years) 58 (32–89) 59 (33–80) 58 (32–89) 58 (33–80) 59 (32–89)
Cause (HBV/HCV/Alcohol/Others,
%)
242 (76.1)/ 33 (10.4)/ 25 (7.9) /
18 (5.7)
123 (71.9)/ 26 (15.2)/ 12 (7.0)/
10 (5.8)
119 (81.0)/ 7 (4.8)/ 13 (8.8)/
8 (5.4)
100 (77.5)/ 14 (10.9)/ 8 (6.2)/
7 (5.4)
142 (75.1)/ 19 (10.1)/ 17 (9.0)/
11 (5.8)
Platelet counts (×103/mm3) 139.6 ± 86.5 121.1 ± 63.9 161.1 ± 103.1 121.8 ± 64.9 151.7 ± 96.9
ALT (IU/L) 39.0 (1.0–2,430.0) 35.0 (1.0–2,430.0) 42.0 (6.0–503.0) 39.0 (1.0–2,430.0) 39.0 (6.0–503.0)
Total bilirubin (mg/dL) 1.0 (0.2–26.9) 0.9 (0.2–9.4) 1.2 (0.2–26.9) 0.9 (0.2–7.8) 1.1 (0.2–26.9)
Albumin (g/dL) 3.5 ± 0.6 3.7 ± 0.4 3.4 ± 0.5 3.6 ± 0.6 3.5 ± 0.6
Prothrombin time (%) 79.4 ± 18.0 81.3 ± 17.6 77.1 ± 18.2 80.4 ± 18.4 78.6 ± 17.7
Child-Pugh class (A/ B/ C, %) 200 (62.9)/ 91 (28.6)/ 27 (8.5) 128 (74.9)/ 36 (21.1)/ 7 (4.1) 72 (49.0)/ 55 (37.4)/ 20
(13.6)
99 (76.7)/ 26 (20.2)/ 4 (3.1) 101 (53.4)/ 65 (34.4)/ 23 (12.2)
Tumor size (cm) 5.5(0.8–26.5) 3.0 (0.8–18.6) 10.0 (1.0–26.5) 3.0 (0.8–17.4) 7.9 (1.3–26.5)
Tumor number, solitary (%) 144 (45.3) 93 (54.4) 51 (34.7) 74 (57.4) 70 (37.0)
Presence of PVT (%) 107 (33.6) 24 (14.0) 83 (56.5) 23 (17.8) 84 (44.4)
Presence of metastasis (%) 62 (19.5) 14 (8.2) 48 (32.7) 11 (8.5) 51 (27.0)
Tumor stage (I/ II/ III/ IVa/ IVb, %) 41 (12.9)/ 76 (23.8)/ 85 (26.7)/
64 (20.1)/ 52 (16.4)
34 (19.9)/ 57 (33.3)/ 51 (29.8)/
17 (9.9)/ 12 (7.0)
7 (4.8)/ 19 (12.9)/ 34 (23.1)/
47 (32.0)/ 40 (27.2)
30 (23.3)/ 40 (31.0)/ 35 (27.1)/
18 (14.0)/ 6 (4.7)
11 (5.8)/ 36 (19.0)/ 50 (26.5)/ 46 (24.3)/
46 (24.3)
AFP (ng/mL) 92.3 (1.6–2,753,500.0) 28.9 (1.6–331,580.0) 350.0 (2.2–2,753,500.0) 32.3 (1.7–331,580.0) 207.1 (1.6–2,753,500.0)
CRP (mg/L) 4.7 (0.1–343.6) 1.2 (0.1–6.3) 24.9 (6.4–343.6) 1.7 (0.1–64.8) 14.3 (0.2–343.6)
NLR 2.6 (0.6–49.9) 1.8 (0.6–13.0) 4.0 (0.7–49.9) 1.5 (0.6–2.2) 3.8 (2.3–49.9)


















Table 2 Univariate and multivariate analysis of prognostic factors of overall survival by Cox regression model
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Sex (male) 0.842 (0.604–1.173) 0.309
Age > 60 (years) 0.777 (0.586–1.031) 0.080
Cause (viral) 0.978 (0.652–1.469) 0.916
ALT > 40 (IU/L) 1.511 (1.146–1.992) 0.003 1.333 (0.985–1.804) 0.062
Child-Pugh class 1.803 (1.480–2.198) < 0.001 1.711 (1.377–2.125) < 0.001
Tumor size > 5 (cm) 3.548 (2.622–4.801) < 0.001 1.778 (1.209–2.615) 0.003
Tumor multiplicity (≥ 2) 2.023 (1.510–2.711) < 0.001 1.391 (1.023–1.892) 0.035
Presence of PVT 4.197 (3.141–5.609) < 0.001 1.827 (1.284–2.598) 0.001
Presence of metastasis 3.002 (2.178–4.139) < 0.001 1.242 (0.868–1.779) 0.236
AFP > 200 (ng/mL) 2.783 (2.099–3.690) < 0.001 1.734 (1.248–2.407) 0.001
CRP > 6.3 (mg/L) 3.923 (2.929–5.255) < 0.001 1.519 (1.049–2.199) 0.027
NLR > 2.3 3.050 (2.223–4.185) < 0.001 1.601 (1.124–2.280) 0.009
HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; PVT, portal vein thrombosis; AFP, α-fetoprotein; CRP, C-reactive protein; NLR,
neutrophil-to-lymphocyte ratio.
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changes in CRP concentrations or NLR serially
measured before and after therapy could predict tumor
response. At follow-up, compared with responders,
patients with progressive disease showed an increase in
levels of CRP and NLR. In contrast, responders exhibited
a decrease in serial measurement of serum CRP and
NLR (Figures 3B and 3C). There were statistically signifi-
cant differences in the CRP and NLR changes between
responders and those with progressive disease (all
p < 0.001, repeated measures ANOVA).
Discussion
The present study focused on the predictive value of CRP
and NLR in the outcome of patients with HCC. From the
analysis of a large cohort, we found that elevated CRP and
NLR independently predicted worse survival in patients with
HCC. In this study, CRP and NLR were utilized as prognos-
tic indicators of HCC which appeared to be more evident
when used in combination. This is probably due to the sig-
nificant synergistic effect of the two inflammatory markers.
Moreover, these markers correlated well with tumor re-
sponse, as evidenced by serial measurements. The significant
prognostic role of CRP and NLR is supported by the
evidence that the levels of both markers displayed a linear
relationship with the progressing stage of tumor and Child-
Pugh classification, known as the two key prognostic factors
for HCC.
There have been not yet clear explanation how
elevated CRP and NLR would be responsible for tumor
progression. Some studies have compiled the possible
roles of CRP in cancer development as follows: i) anti-
apoptotic activity and tumorigenic potency by over ex-
pression of IL-6, ii) T cell impairment, iii) resistance tochemotherapy, and iv) increased levels of serum
angiogenic factors [23]. The levels of CRP have been in-
versely related to tumor-infiltrating CD4+ T-lymphocytes
within the tumor microenvironment, which in turn carriers
a poor prognosis [24]. Because not only normal hepatocytes
but also hepatoma cells can produce serum CRP [25], it
could be regarded that elevated CRP is related to hepatic
tumor burden, and this has supporting evidence [7].
Although measured easily, NLR is more complicated
due to its special feature as a combined factor of inflam-
mation and host immune reaction. Increased counts of
neutrophil can provide an adequate environment for
tumor growth and even metastasis via angiogenesis. One
study showed that neutrophils enhance tumor invasion
via paracrine regulation mediated by neutrophil-derived
hepatocyte growth factor [26]. The accumulated IL-17
-recruited neutrophils into peritumoral stroma of HCC
were the major source of matrix metalloproteinase-9,
which stimulates proangiogenic activity in HCC [27].
Circulating vascular endothelial growth factor, a key
proangiogenic factor, is contained in granulocyte, par-
ticularly in the neutrophils [28]. Neutrophil can contrib-
ute to cancer metastasis via promoting motility of
cancer cells and adhesion to hepatic sinusoids [29,30].
Since neutrophil could also suppress T cell activation
through the production of arginase, nitric oxide and re-
active oxygen species [31], it induces depletion of
lymphocyte-mediated immune response. Weaker im-
mune reaction due to relative lymphocytopenia and
elevated NLR could explain for depletion of tumor-
infiltrating lymphocytes that are independently predict-
ive of cancer-specific survival [32].
With multivariate analysis, the present study revealed
Child-Pugh class, tumor size, tumor multiplicity,
Figure 1 Kaplan-Meier curves for overall survival probability according to (A) CRP, (B) NLR and (C) a combination of CRP and NLR.
(A) Patients with CRP > 6.3 mg/L (dotted line) had a significantly shorter overall survival than those with CRP≤ 6.3 mg/L (solid line) (median 6.0
vs. 26.9 months, respectively; p < 0.001). (B) Likewise, survival among patients with NLR > 2.3 (dotted line) was shorter than those with NLR≤ 2.3
(solid line) (median 7.9 vs. 32.5 months, respectively; p < 0.001). (C) There is a significantly longer survival in the group with both CRP≤ 6.3 mg/L
and NLR≤ 2.3 (solid line, 39.2 months) than the group with either CRP > 6.3 mg/L or NLR > 2.3 (dashed line, 14.6 months) or than the group with
both CRP > 6.3 mg/L and NLR > 2.3 (dotted line, 4.6 months).
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factors predictive of outcome of HCC. A recent study
evaluating CRP and NLR in transplant recipients with
HCC showed that CRP did not affect overall patient
survival, but NLR did with statistical significance [33].
The discrepancy could be due to some differences in
assays measuring CRP and the study population. Our
study employed a high-sensitivity CRP with cut-off value
6.3 mg/L, whereas the study detected CRP with a
conventional sensitivity with cut-off value 1 mg/dL(= 10 mg/L). Additionally, our study recruited patients
with various stages of HCC undergoing different treat-
ment modalities, which is a distinction to the study
recruiting patients with limited stages of HCC undergo-
ing transplantation, which could result in no more
lasting inflammation. There is no consensus on the cut-
off value for NLR. It has been therefore set empirically
between 2.42 and 5 in studies [5,14-20]. In this analysis,
the cut-off value of 2.3 for NLR offered the most signifi-
cant association with the patient outcomes. Further
Figure 2 Correlations between (A) CRP and Child-Pugh class, (B) CRP and tumor stage, (C) NLR and Child-Pugh class, (D) NLR and
tumor stage, and (E) CRP and NLR. The levels of CRP and NLR tends to escalate with aggravating Child-Pugh class from A to C (A, r = 0.311,
p < 0.001; C, r = 0.306, p < 0.001) or progressing tumor stage from I to IV (B, r = 0.475, p < 0.001; D, r = 0.358, p < 0.001). (E) There is a significant
positive inter-correlation between CRP and NLR (r = 0.570, p < 0.001).
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point of CRP and NLR in predicting prognosis in
patients with HCC.
In our results, it is interesting to note that an elevated
CRP level was strongly associated with an elevated NLR.
It seems to be due to some relationship between these
two markers in terms of host inflammation and immune
reaction, as evidenced by the observations that high CRP
levels associated with inflammation are inversely relatedto low-level tumor lymphocyte infiltration, which may
contribute to an elevated NLR [24]. Although they had
modest individual associations on the prognosis of the
patients, the significance was quite stronger when used
in combination. It is of note that both CRP and NLR
levels were significantly related to tumor burden and
underlying hepatic reserve, known as the two key
determinants of HCC survival, showing a linear positive
relationship with tumor stages or Child-Pugh classes.
Figure 3 Tumor response according to baseline levels of serum (A) CRP and NLR and changes in (B) CRP and (C) NLR levels after
therapy. Tumor response was better in the group with both baseline serum CRP ≤ 6.3 mg/L and NLR ≤ 2.3 than the other groups (p < 0.001;
Figure 3A). At follow-up, patients with progressive disease showed an increase in levels of CRP and NLR, whereas responders exhibited a decrease
in the levels (repeated measures ANOVA, all p < 0.001; Figure 3B and 3C). CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease.
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synergistically enhanced with combined use of them, as
presented in our survival analysis.
Moreover, our results showed that patients with
elevated CRP and NLR had worse treatment response,
while those with a low-level of CRP and NLR had more
favorable response. Consistent with survival analysis,
there were significant differences in tumor response on
the combined use of serum CRP level and NLR. Serial
measurements of CRP and NLR exhibited a reduction in
CRP and NLR among responders as well as their rise in
progressive disease during treatment. Thus, it is
expected that the outcome of treatment response before
and during management would be predictable to some
extent with the levels of CRP and NLR.
The current study has some limitations. There is some
heterogeneity in treatment used for HCC, and the ma-
jority of the patients received TAC-based loco-regional
therapy, with limited number of surgical cases, which
could have affected the outcome. However, the prognos-
tic effect of those inflammatory markers was still appar-
ent when analyzed specifically in selected patients
receiving loco-regional therapies. Although there are
many other conditions affecting the levels of CRP and
NLR, like an infectious state and autoimmune disease,
the possibility may be minimized because most of those
markers were indeed tested prior to treatment, without
evidence of serious infection. Rather, the results of our
study could be reliable, because we described the largest
cohort to date of consecutive patients and provided
comprehensive data from serial measurements of CRPand NLR simultaneously, which have not been explicitly
evaluated thus far.
Conclusions
In summary, this study demonstrated that CRP and NLR
are not only markers of inflammation, but also inde-
pendent prognostic indicators for HCC, reflecting tumor
burden and hepatic reserve. Their role as a surrogate
marker for tumor response and survival is more
enhanced when used in combination. Further studies are
needed to confirm and update a more detailed clinical
relevance and biological mechanisms of CRP and NLR.
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